
Big pharma pushes Trump team to ease Medicare drug price negotiation rules
By Michael Erman, Patrick Wingrove and Maggie Fick NEW YORK (Reuters) – The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump is back in office, according to lobbyists, executives, analysts and healthcare policy experts. Seven lobbyists and executives…